News

Prof. Teesalu delivered a seminar "Development of homing peptides for precision guided delivery of nanoparticles" in the framework of the 7th Science and the Action seminar series.

Laboratory of Precision and Nanomedicine is an active  member of the COST Action CA17140  - the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies.

https://uniwersytetlodzki-my.sharepoint.com/personal/joanna_korczynska_adm_uni_lodz_pl/_layouts/15/onedrive.aspx?id=%2Fpersonal%2Fjoanna%5Fkorczynska%5Fadm%5Funi%5Flodz%5Fpl%2FDocuments%2FPROJEKTY%20REALIZOWANE%2FCOST%5FBKM%2FSATA%2F7%5FJune%203%2FNano2Clinic%20%2D%20Science%20and%20the%20Action%20Seminar%20series%20%5F%20June%203%2D20220603%5F150058%2DNagrywanie%20spotkania%20%282%29%2Emp4&parent=%2Fpersonal%2Fjoanna%5Fkorczynska%5Fadm%5Funi%5Flodz%5Fpl%2FDocuments%2FPROJEKTY%20REALIZOWANE%2FCOST%5FBKM%2FSATA%2F7%5FJune%203&ga=1

In collaboration with the lab of Dr. Maria J. Vicent at the Principe Felipe Research Center in Valencia, Spain, we report development of a new peptide-guided nanosystem called "OximUNO". OximUNO, by removing the mannose receptor-positive macrophages from the tumor, was safe and effective in treating triple negative breast cancer in mice. OximUNO comprises a star-shaped polyglutamate (St-PGA) decorated with the CD206-targeting peptide mUNO that carries the chemotherapeutic drug doxorubicin (DOX). In the TNBC model, a fluorescently labelled mUNO-decorated St-PGA homed to CD206+ TAMs within primary lesions and metastases. OximUNO exhibited no acute liver or kidney toxicity in vivo. Treatment with OximUNO reduced the progression of primary tumour lesions and pulmonary metastases, significantly diminished the number of CD206+ TAMs and increased the CD8/FOXP3 expression ratio (indicating immunomodulation). Our findings suggest the potential benefit of OximUNO as a TAM-depleting agent for TNBC treatment. Importantly, our studies also represent a novel design of a peptide-targeted St-PGA as a targeted therapeutic nanoconjugate.

Paper:

https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-22-0043/704874/Depletion-of-Mannose-Receptor-Positive-Tumor

Media:

https://meditsiiniteadused.ut.ee/en/node/139971?fbclid=IwAR0WNBefobanP8t1-pN20NuZKtWPx8tvvZjducvYL52GYhRNysDeUullKUs

https://tervis.postimees.ee/7544640/uus-ravim-voimaldab-tulevikus-loodetavasti-ravida-agressiivset-rinnavahki-edukamalt

https://novaator.err.ee/1608629164/vaike-valgujupp-muutis-vahiravimi-tappisrelvaks

https://www.eurekalert.org/news-releases/956479

 

Our recent publication in the journal Proceedings of the National Academy of Sciences (PNAS) explains how the SARS-CoV-2 coronavirus can hijack an intracellular pathway to increase its infectivity. In collaboration with researchers at the University of Bristol (Dr. Boris Simonetti, Dr. Peter Cullen, Dr. Yohei Yamauchi), we studied how the SARS-CoV-2 and other viruses use the host intracellular machinery to enter into the cells. We previously showed that neuropilin-1 (NRP-1) is a co-receptor of the SARS-CoV-2 virus and that the binding to NRP-1 through the specific CendR motif displayed on the spike protein facilitates the cellular entry an infectivity of the virus. In this new study, we show how the NRP-1 and its ligands (nanoparticles displaying the CendR motif) are intracellularly transported by the ESCPE-1 protein complex. Knocking down essential proteins of the ESCPE-1 complex significantly decreased the internalization of the nanoparticles and, importantly, the infectivity of the corona virus. These findings could serve to develop new therapeutics that can interfere with the ESCPE-1 complex and prevent the NRP-1-mediated infection of the SARS-CoV-2 virus and other viruses.  

Media:

https://www.sciencedaily.com/releases/2022/06/220614095546.htm

We are pleased to announce that our success in applying for Euronanomed grants continues. In November of 2021 it was announced that application “LDL-like nanoparticles for CAR-T-based glioblastoma immunotherapy” by our consortium led by Dr. Pablo Hervella (Instituto de Investigación Sanitaria de Santiago de Compostela, Spain) was successful. This project will seek to demonstrate that the targeted delivery of exogenous antigens to the extracellular matrix (ECM) of brain tumors provides a safe and specific target for chimeric antigen receptor T- cell (CART) for glioblastoma (GBM) treatment.

In November of 2020 our team participated in two high-profile studies in Science that demonstrated that as SARS-CoV2 coronavirus matures, an enzymatic event causes the virus to present a specific peptide motif (C-end Rule or CendR peptide), and makes it accessible to bind with a widely-expressed class of mammalian NRP receptors. These reports focused on experiments to rigorously demonstrate the link between SARS-CoV2 and NRP-1, and we did not have sufficient space to discuss what we see as a fascinating and impactful emerging theme, namely that the NRP-1 pathway appears to influence viral infections in a generalized and widely-applicable manner.

In the current PNAS Perspective entitled “A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction”, together with Drs Giuseppe Balistreri and Yohei Yamauchi (virologists at University of Helsinki and Bristol, respectively) we outline  data-driven hypothesis and “connect the dots” to suggest that it is possible (and, indeed, likely) that NRP plays a critical role in infectivity and spread of multiple human pathogenic viruses. This model is seemingly relevant for any virus whose life cycle includes processing by the furin family of proteases, and that list includes a wide range of viruses that pose significant global health concerns, such as Influenza H5N1, Ebola, Dengue, Zika, West Nile, Yellow fever virus, Human Immunodeficiency virus, Hepatitis B virus, and Human Papilloma Virus. 

An essential therapeutic implication of this concept is that a generalized approach to elicit pharmacological interference with the CendR/NRP-1 axis may offer an opportunity to attenuate the infectivity of all of these viruses!

We continue working on development of the further insight into the CendR/virus axis.

Reference: Proc Natl Acad Sci U S A, . 2021 Nov 16;118(49):e2112457118. A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction. Giuseppe Balistreri, Yohei Yamauchi, Tambet Teesalu

The fall of 2021 has been very successful  for our PhD students - Valeria Sidorenko, Allan Tobi and Kristina Põšnograjeva received prestigious grants from the Foundation of University of Tartu. 

Valeria received a memorial scholarship from Valda and Bernard Õun Memorial Foundation in the amount of 5000 euros for attending an international conference.

Allan received the Hilda and Harry Mägi stipend for the amount of 2000€ to support further research and studies.

Kristina received a stipend of 2500 euros from the memorial fund of Liisa Kolumbus that she will use to attend an international conference.

Congratulations to our talented PhD students!

The research labs of the Department of Biomedicine (Molecular Pathology, Molecular Genetics, RNA Biology, and Precision and Nanomedicine) had a traditional joint Science Day on which graduate students reported on the progress of their projects. The event was held in beautiful Sangaste castle and was full of stimulating talks and Q&A sessions. Presentation by our PhD student Kristina Põšnograjeva “Searching for blood brain barrier penetrating peptides” was voted the winner of the best presentation prize for the best  presentation. Congratulations, Kristina!!!

In a study reported in Angewandte Chemie we report the development of Utorubicin (UTO) as a potent anticancer payload of polymeric nanoparticles. Nanoencapsulation of UTO in polymeric vesicles functionalized with tumor-penetrating peptides increases the cytotoxicity of the drug in receptor-positive cells in vitro and, after systemic administration into mice bearing triple-negative tumors, potentiates UTO accumulation in malignant tissue.

This collaborative study was led by team of Precision and nanomedicine (Lorena Simón-Gracia, Valeria Sidorenko,  Tambet Teesalu) and involved Estonian drug development company Toxinvent Inc.

Links:

  1. Novel Anthracycline Utorubicin for Cancer Therapy, Angew Chem, 2021 Jul 26;60(31):17018-17027. https://onlinelibrary.wiley.com/doi/10.1002/anie.202016421
  2. Nanoparticles Could Help to Deliver Cancer-Drug to the Right Target, https://researchinestonia.eu/2018/12/20/nanoparticles-could-help-to-deliver-cancer-drug-to-the-right-target/
  3. Smart specialisation project “Innovative anticancer drug candidates based on a novel cytotoxic compound, Utorubicin

With the global benefits of the new science of nanomedicine growing each year, the University of Tartu is determined to stay at the forefront of the international collaborative research in this area.

We are pleased to announce that outstanding researcher, educator, and raising star in nanomedicine, Prof. Hélder A. Santos, joins the Laboratory of Precision and Nanomedicine of University of Tartu as a Visiting Professor (effective February 1st, appointment for 2 years).

Prof Santos is a physical chemist specialized in electrochemistry, biological mimetic models and soft interfaces. His current work bridges engineering, pharmaceutical and medical research. His research focus is in the use of biodegradable and biocompatible nanoporous silicon nanomaterials, polymers, the application of microfluidics technology for nanoparticle production for controlled drug delivery, diagnosis and treatment of cancer, diabetes, and cardiovascular diseases, and further clinical translation of these nanotechnologies. Currently, is a Full Professor in Pharmaceutical Nanotechnology, Head of the Nanomedicines and Biomedical Engineering Group, and Director of the Doctoral Program in Drug Research at the Faculty of Pharmacy, at the University of Helsinki. He is also a Fellow Member of Helsinki Institute of Life Science (HiLIFE), the Director of the FinPharmaNet (The Network of Drug Research Doctoral Programmes in Finland), Chair of Controlled Release Society Focus Group in Nanomedicine and Nanoscale Delivery, and Chairman and co-founder of Capsamedix Oy.

The involvement of Prof. Santos will further strengthen the collaborative ties between the research labs and institutions to further facilitate collaborative efforts in translational nanomedicine and training of next generation of nanomedicine experts.

https://www.helsinki.fi/en/researchgroups/nanomedicines-and-biomedical-engineering/research-team/about-prof.-santos

https://scholar.google.com/citations?user=K3Pj_gwAAAAJ&hl=fi

 

Contact info: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

In vivo phage display is widely used for the identification of organ- or disease-specific homing peptides. In our study (lead authors PhD students Karlis Pleiko and Kristina Põšnograjeva), we developed new tools to streamline in vivo biopanning screens.  Our approach allows differential mapping of homing ability and organ-selectivity of peptide-displaying phages during in vivo selection based solely on the high throughput sequencing data. This study will accelerate mapping of vascular heterogeneity in vivo and, ultimately, catalyze progress toward development of affinity-guided smart drugs and contrast agents.

“In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues”, Pleiko K, Põšnograjeva K, Haugas M, Paiste P, Tobi A, Kurm K, Riekstina U, Teesalu T; Nucleic Acids Research, (2021 Jan 14; https://doi.org/10.1093/nar/gkaa1279); “;

https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkaa1279/6097687

 

Page 1 of 7